Literature DB >> 2757916

Reassessment of the relationship between M-protein decrement and survival in multiple myeloma.

M Palmer1, A Belch, J Hanson, L Brox.   

Abstract

The relationship between percentage M-protein decrement and survival is assessed in 134 multiple myeloma patients. The correlation did not achieve statistical significance (P = 0.069). Multivariate analysis using the Cox proportional hazards model, including a number of previously recognised prognostic factors, showed only percentage M-protein decrement, creatinine and haemoglobin to be significantly correlated with survival. However, the R'-statistic for each of these variables was low, indicating that their prognostic power is weak. We conclude that neither the percentage M-protein decrement nor the response derived from it can be used as an accurate means of assessing the efficacy of treatment in myeloma. Mature survival data alone should be used for this purpose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2757916      PMCID: PMC2246972          DOI: 10.1038/bjc.1989.22

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  5 in total

1.  Combination chemotherapy for multiple myeloma.

Authors:  R Alexanian; J Bonnet; E Gehan; A Haut; J Hewlett; M Lane; R Monto; H Wilson
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

2.  Are the current criteria for response useful in the management of multiple myeloma?

Authors:  M Palmer; A Belch; L Brox; E Pollock; M Koch
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

3.  The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments.

Authors:  R D Wochner; W Strober; T A Waldmann
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

4.  Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.

Authors:  H J Cohen; A A Bartolucci; W B Forman; H R Silberman
Journal:  J Clin Oncol       Date:  1986-06       Impact factor: 44.544

5.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.